News from valeant pharmaceuticals international, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 29, 2015, 06:00 ET
Valeant Pharmaceuticals International, Inc.

Valeant Announces CFO Succession Plan And Additional Executive Appointment

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that Howard B. Schiller has advised the Company of his decision...

Apr 29, 2015, 06:00 ET
Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals Reports First Quarter 2015 Financial Results

2015 First Quarter Results - Total Revenue $2.2 billion; an increase of 16% over the prior year despite negative foreign exchange impact of...

Apr 24, 2015, 09:14 ET
Valeant Pharmaceuticals International, Inc.

RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced...

Apr 09, 2015, 08:00 ET
Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals To Announce 2015 First Quarter Results On April 29, 2015

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast...

Apr 01, 2015, 17:00 ET
Valeant Pharmaceuticals International, Inc.

Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019

Salix Pharmaceuticals, Ltd. (the "Company" or "Salix"), a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX)...

Apr 01, 2015, 17:00 ET
Valeant Pharmaceuticals International, Inc.

Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 2.75% Convertible Senior Notes Due 2015

 Salix Pharmaceuticals, Ltd. (the "Company" or "Salix"), a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX)...

Apr 01, 2015, 09:05 ET
Valeant Pharmaceuticals International, Inc.

Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021

 Salix Pharmaceuticals, Ltd. ("Salix"), a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX:VRX), today...

Apr 01, 2015, 09:00 ET
Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Salix Pharmaceuticals

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has completed the previously announced acquisition of Salix...

Apr 01, 2015, 06:00 ET
Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd.

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced the expiration of the tender offer (the "Offer")...

Mar 27, 2015, 10:09 ET
Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced today the closing of its previously announced registered offering...

Mar 17, 2015, 09:00 ET
Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals Prices Offering Of $1.45 Billion Of Common Shares

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) has priced its previously announced registered offering of common shares in the...

Mar 16, 2015, 16:01 ET
Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals Announces Offering Of $1.45 Billion Of Common Shares

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced today that it has filed with the U.S. Securities and Exchange...

Mar 16, 2015, 08:00 ET
Valeant Pharmaceuticals International, Inc.

Valeant And Salix Agree On Amended Terms To Merger Agreement

- $173 PER SHARE CASH OFFER THROUGH APRIL 7TH - TRANSACTION EXPECTED TO CLOSE APRIL 1ST  Valeant Pharmaceuticals International,...

Mar 13, 2015, 15:48 ET
Valeant Pharmaceuticals International, Inc.

Valeant Announces HSR Clearance For Salix Acquisition

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that it has received early...

Mar 13, 2015, 09:26 ET
Valeant Pharmaceuticals International, Inc.

Valeant Announces Pricing Of Private Offering Of Senior Notes

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that VRX Escrow Corp., a newly...

Mar 11, 2015, 18:10 ET
Valeant Pharmaceuticals International, Inc.

Valeant Comments On Endo Offer To Acquire Salix

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today issued the below statement in response to Endo International PLC's...

Mar 09, 2015, 16:40 ET
Valeant Pharmaceuticals International, Inc.

Valeant Announces Launch Of Private Offering Of Senior Notes

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced today that VRX Escrow Corp., a newly formed wholly owned Canadian...

Feb 25, 2015, 08:00 ET
Valeant Pharmaceuticals International, Inc.

PROVENGE® (sipuleucel-T) Demonstrates Sustained Immune Response Two Years after Treatment in Biochemically-Recurrent Prostate Cancer

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced the presentation of new long-term, preliminary results...

Feb 22, 2015, 16:00 ET
Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results

2014 Fourth Quarter Results - Total revenue $2.3 billion; an increase of 10% over the prior year despite negative foreign exchange impact...

Feb 22, 2015, 16:00 ET
Valeant Pharmaceuticals International, Inc.

Valeant To Acquire Salix Pharmaceuticals For $158.00 Per Share In Cash

- Salix is the Leader in the Growing U.S. Gastrointestinal Market - Transaction Creates a New Specialty Platform for Growth -...